JAGUAR HEALTH, INC. Cash
JAGUAR HEALTH, INC. (JAGX) had Cash of $3.79 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-08-19
- 2026-06-30: Cash $3.79M.
- 2026-03-31: Cash $7.28M.
- 2025-12-31: Cash $968.00K.
- 2025-06-30: Cash $2.21M.
| Period end | Cash |
|---|---|
| 2026-06-30 | $3.79M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $7.28M 10-Q · filed 2026-05-20 |
| 2025-12-31 | $968.00K 10-K · filed 2026-04-07 |
| 2025-06-30 | $2.21M 10-Q · filed 2026-08-19 |
| 2025-03-31 | $5.69M 10-Q · filed 2026-05-20 |
| 2024-12-31 | $8.00M 10-K · filed 2026-04-07 |
| 2021-03-31 | $35.00M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $33.80M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |